Magnetic nanotags (MNTs) are a promising alternative to fluorescent labels in biomolecular detection assays, because minute quantities of MNTs can be detected with inexpensive giant magnetoresistive (GMR) sensors, such as spin valve (SV) sensors. However, translating this promise into easy to use and multilplexed protein assays, which are highly sought after in molecular diagnostics such as cancer diagnosis and treatment monitoring, has been challenging. Here, we demonstrate multiplex protein detection of potential cancer markers at subpicomolar concentration levels and with a dynamic range of more than four decades. With the addition of nanotag amplification, the analytic sensitivity extends into the low fM concentration range. The multianalyte ability, sensitivity, scalability, and ease of use of the MNT-based protein assay technology make it a strong contender for versatile and portable molecular diagnostics in both research and clinical settings.
A
consensus is emerging that early detection and personalized treatment in clinics based on genetic and proteomic profiles of perhaps 4-20 biomarkers are the key to improving the survival rate of patients with complex diseases, such as cancer, autoimmune disorders, infectious diseases, and cardiovascular diseases (1) (2) (3) . Although the tools for large-scale biomarker discovery with hundreds to thousands of biomarkers are available, there are few biomolecular detection tools capable of multiplex and sensitive detection of protein biomarkers that can be readily adopted in clinical settings for biomarker validation and for personalized diagnosis and treatment. This need, we believe, can be fulfilled by the magnetic nanotag (MNT)-based biomolecular assay technology reported here. We demonstrate the feasibility and implementation of this technology with multiple potential cancer markers.
Several research groups are investigating MNT (4-6)-based analyte quantification as a highly sensitive alternative to optical biosensors and biochips (7) (8) (9) (10) . By labeling the target analyte of interest with MNTs (see Fig. 1 ), analyte detection and quantification can occur when the analyte binds to capture probes on the surface of giant magnetoresistive (GMR) sensors (11) (12) (13) (14) (15) such as spin valve (SV) sensors (16) , which have been developed and optimized for use in hard disk drives on a scale of hundreds of millions of units annually with great economy and reliability. Such sensors, when modified for use in biological applications, were previously shown to be capable of detecting as few as 10 MNTs (13, 16) .
Results
Given the recent efforts to develop methods for early cancer detection via quantification of cancer-related cytokines, we chose the following analytes for our MNT-based protein assays: cancer embryonic antigen (CEA), eotaxin, granulocyte colonystimulating factor (G-CSF), interleukin-1-alpha (IL-1␣), interleukin-10 (IL-10), IFN gamma (IFN-␥), lactoferrin, and tumor necrosis factor alpha (TNF-␣). Fig. 1 outlines the detection scheme in which analyte is captured on the sensor surface and quantified with streptavidin-coated MNTs. Typically, the analyte and linker antibody incubation time ( Fig. 1 B and C) is 1 h or less, whereas the MNT-based quantification (Fig. 1D ) requires Ͻ15 min. It is possible to reduce the total assay time to Ͻ30 min, for example through analyte incubation in a microfluidic channel (17) , so that it is suitable for physician office laboratory or point of care applications. We currently implement the MNT detection scheme on a custom fabricated chip, which has an array of 64 SV sensors and a 200-l reaction well placed on top [see Supporting Information (SI)], so that the reagents can be pipetted and aspirated easily. At present, our prototype electronic instrumentation (see methods) is able to record up to 64 sensors in Fig. 1 . Magnetic nanotag-based protein detection assay. Probe sensors are functionalized with capture antibodies specific to the chosen analyte, whereas control sensors are blocked with a 1 wt% BSA solution (A). During analyte incubation, the probe sensors capture a fraction of the analyte molecules (B). A biotinylated linker antibody is subsequently incubated, which binds to the captured analyte (C), and which provides binding sites for the streptavidin-coated magnetic nanotags. Streptavidin-coated magnetic nanotags are then incubated (D), and the nanotag binding signal, which saturates at an analyte concentration-dependent level, is used to quantify the analyte concentration.
real-time, with an update rate of 64 data points every 5 s. Some of the sensors are covered with epoxy and used to record an electronic reference signal, so that nonbiological signal components such as temperature drift can be corrected.
Typical binding curve data (signal vs. time) from MNT-based immunoassays with multiple probes is shown in Fig. 2 . The moment of MNT application is defined as t ϭ 0. Beginning at t ϭ 0, the signal rise reflects the binding of MNTs to the SV sensor surface in real time. As a result of the indirect labeling method used here, the real-time data contains information about the MNT-binding kinetics rather than the analyte binding kinetics, but the saturation level of an MNT-binding curve is taken as a direct measure of binding site abundance on the sensor surface, which in turn is determined by the concentration of the previously applied analyte. In addition to analyte quantification, the real-time MNT-binding curves are also used to identify and eliminate sources of error, as they help to distinguish proper (continuous, steady, saturating) from improper (discontinuous, noisy, drifting) sensor operation. For example, the fact that the signal quickly stabilizes despite an excess amount of nanotags in the solution indicates that in the absence of suitable binding sites, the nanotags do not precipitate or bind spontaneously. This is an important prerequisite for precise analyte quantification. The MNT-binding curves also reliably give the time needed for reaching signal saturation, that is, MNT-binding equilibrium. Typically the net signal gains at time t ϭ 15 min are reported to compare different assay runs, but when few MNT-binding sites are available (due to low analyte concentration), MNT quantification can reach equilibrium in as little as 60 s.
An example of such rapid MNT quantification can be seen in Fig. 2 A. In that experiment, a chip was functionalized with two probes (anti-TNF-␣ and anti-IL-1␣) and one control (BSA), and the applied sample contained 0.6 pM TNF-␣ and 5.6 pM IL-1␣. The resulting binding signals level off approximately one minute after MNT application, and the signal levels of 1.9 V for TNF-␣ (8 sensors) and 4.1 V for IL-1␣ (4 sensors) are significantly larger and distinct from the nonspecific signal of 0.6 V on the BSA-functionalized control sensors.
A similarly functionalized chip was exposed to a 5.7 pM TNF-␣ in 50% serum, as shown in Fig. 2B . The resulting average signal saturates at 3.2 V after approximately two minutes. The negative controls, consisting of both the anti-IL-1␣-and BSAfunctionalized sensors, report an average of 0.1 V (range ϩ 0.3 V to Ϫ0.3 V), which indicates an average signal to background ratio of 32:1 at this concentration.
To demonstrate the signal vs. concentration scaling relationship of an analyte in 50% serum over large changes in analyte concentrations, we ran a series of MNT-based immunoassays to detect human chorionic gonadotropin (hCG) that was spiked into 50% serum. For this test, hCG was chosen as a model analyte because reference hCG samples, high quality antibodies, and comparable commercial hCG assays are readily available. The results are shown in Fig. 2C . The lowest hCG concentration, 2.4 pM in 50% serum, resulted in a 14-sensor median signal of 13.6 V (max 27, min 8.2, SD of 4.6), and for each 10-fold increase in hCG concentration, the signal approximately doubled. The results demonstrate that we can detect hCG concentrations over at least four orders of magnitude, down to the serum baseline level, which is approximately 1 pM (18) . Performing the same assay in analyte-free PBS (Fig. 2C control assay) shows that the control signal is in a range of 2.5-3.5 V rms , which is significantly lower than the signal expected from 1 pM hCG in serum. Extrapolation of the scaling trend down to the background level indicates that our MNT-based assay can detect approximately 10 femtomolar concentrations of hCG in serum, which is better than the sensitivity of commercial ELISA kits we have compared (Ϸ4 pM). The amount of data scatter is also comparable to commercial immunoassays and possibly the result of uneven probe molecule distribution, which is a common artifact in spotted microarrays (19) . The higher signal and background levels of Fig. 2C (when compared to Fig. 2 A and B) were achieved by successively adsorbing not one but three layers of nanotags, that is, by a means of in situ nanotag amplification (see methods). The nanotag amplification is useful when the signal levels are so low, relative to the electrical noise of the system, that they are difficult to quantify. In such cases, nanotag amplification can often elevate the signal levels well above the quantification threshold, which leads to more consistent results. Assay results obtained this way are highly reproducible, and third party serum samples with unknown hCG concentrations have been quantified with good accuracy, simply by referencing the signal levels against the standard curve in Fig. 2C . Fig. 3 shows the result of a multianalyte, multiprobe assay performed on a single chip. For this test, seven different regions of the chip were functionalized, each with one of seven capture antibodies. Additional control sensors were functionalized with BSA or epoxy. The chip was then exposed to a mixed sample containing the seven potentially recognized analytes at a concentration of 1 pg/ml each (molar concentrations 5 fM to 119 fM). Twenty-eight sensors were chosen from the sensor array to measure the signals from each of the functionalizations with some redundancy (ranging from replicate to quadruple). The initial MNT quantification was enhanced with two rounds of nanotag amplification. As seen in Fig. 3 , under these conditions the minimal signal to background ratio is 4:1 and better in most cases. Sensors with identical functionalization reported very similar signal levels in most cases, but some functionalizations appear to be more sensitive than others. This is reasonable considering that the analyte affinity of each functionalization can be different. The small but nonzero signals on the BSA control sensors compared with the epoxy control could result from of a small amount of cross-reactivity, which is common in multiplex protein assays and which also depends on the matching and quality of the assay antibodies.
Discussion
Until recently most experiments were focused on proof of concept, that is, modeling and optimization of MNT-sensor interaction (16) , developing the electronic platform (10), estimating the potential of MNT-based assays, for example, when compared with fluorescent assays (14), and demonstrating the principal benefits of incorporating microfluidics and MNT manipulation techniques (20) . Although some efforts have been made to move these concepts into the bioanalytical arena (7) (8) (9) (10) (11) (13) (14) (15) , there are few demonstrations of actual magnetic protein assays of either single or multiple analytes in a buffer or serum sample. In particular, multiple analytes require sophisticated biochemistry as well as control sensors on a single chip to ascertain sensitivity and selectivity at the same time. Selectivity is particularly challenging to achieve in multiplex protein assays and assays involving actual blood serum, where unexpected cross-reactivity can occur much more readily than in DNA hybridization assays. Our experiments demonstrate that MNTbased biomolecular assays are capable of fast and sensitive multiplex protein detection involving real-world serum samples. Another significant advance reported here concerns the magnetic and kinetic properties of the MNTs. Magnetic analyte quantification has been demonstrated for DNA detection and has typically required large magnetic labels that range in size from approximately 250 nm to 3 m (11, 12, 14, 21). These m-sized labels are not optimal for biomolecular assays-they diffuse slowly, are prone to magnetic interaction and subsequent precipitation, and are very bulky compared with the analyte molecules. To overcome these limitations, we have focused on detecting nanometer sized MNTs such as commercially available 50-nm MACS MNTs (see methods), which have a very small magnetic signature but which exhibit long term suspension stability and excellent binding selectivity. To enhance the sensitivity of our assay, the passivation of the SV sensors in this article has been thinned to an unprecedented 30 nm. The resulting sensitivity allows us to reliably detect minute magnetic signatures, such as from MACS MNTs, provided that they are in the immediate proximity of the sensor. By combining small magnetic moment MNTs with very sensitive proximity detection, our sensors primarily detect MNTs that are bound to the sensor surface. If unbound MNTs are stable in suspension, then the signal contribution from these extraneous unbound MNTs is negligible, and washing steps, which are typically required to remove unbound signal-generating labels, can be omitted. In practice, this suppression of unbound labels means that the true amount of currently bound nanotags can be observed in realtime, and that negative control sensors experience no signal shift and return during nanotag application and removal. Simple one-step homogeneous assays with no washing steps are thus a possibility, which would further enhance the use of this technology in clinical applications.
Our 50-nm MNT-based assay overcomes all previous detection shortcomings and presents the most sensitive magnetic detection method for protein arrays to date. With carefully screened antibodies, the sensitivity and selectivity of our MNTbased analyte quantification method is already sufficient for clinically relevant protein detection in real world serum samples, and multiplex protein detection can be readily performed with this method. Individual sensor microspotting (see SI) will allow the accommodation and simultaneous measurement of up to 64 different probes on a chip of the current generation. We expect that significant improvements can also be made on the sensor, for example, using magnetic tunnel junction sensors (9, 22) instead of spin valves, and by using sensors with narrower segments (16) (see SI). In the near future, capture agents with higher affinity, and similarly small but higher magnetic moment MNTs are all expected to enhance the analytic sensitivity of MNT-based assays further. We believe that the demonstrated capability of detecting multiple biomarkers on a single chip, combined with sensitivity, scalability, and ease of use, make this protein assay method a strong contender for portable multiplexed molecular diagnostics at or near point-of-care. It is also notable that MNT-based analyte quantification with SV sensors has several advantages over other methods: The sensors are easy to fabricate, pH-insensitive, and with no ''bleaching'' of MNTs and no magnetic background from bio-systems, MNT-based assays produce signals that are exceptionally stable even during drastic changes of experimental conditions, such as wet to dry transitions. MNT-based analyte quantification can also be conveniently combined with magnetic separation techniques, which should lead to further assay simplifications. For example, analyte extraction and the first round of molecular amplification have already been combined into a single magnetic separation step to achieve an ultrasensitive protein detection (23) , which, however, still relies on optical analyte quantification to obtain the final result. All of these positive attributes will make it easier to translate MNT-based protein assays to clinical settings.
Materials and Methods
Chip Fabrication. On silicon wafers with 150-m thermal oxide, a spin valve film with a layer sequence similar to that of hard disk drives read heads was patterned by ion milling into individual sensors (9), each consisting of 32 linear segments of 1.5 ϫ 100 m connected in series and arranged to cover an area of 100 ϫ 100 m 2 (see SI). Each sensor had a nominal resistance of 40 k⍀ and a maximum magnetoresistance of 12%. Corrosion resistant leads (Ta 5/Au 300/Ta 5) nm were sputter deposited and patterned by lift-off. As suggested elsewhere (24) , the sensors were passivated with a tri-layer oxide (SiO2 10/ Si3N4 10/SiO 2 10) nm that was deposited at room temperature by ion beam sputter deposition. The leads were passivated with an additional tri-layer oxide (SiO2 100/Si3N4 100/SiO2 100) nm. A two-component epoxy (EP5340, Eager Plastics) was used to assemble the chip and reagent well (Tygon tubing, 1/4'' ID ϫ 3/8'' OD, 6 mm long) on the ceramic 84-pin chip carrier (LCC08423, Spectrum Semiconductor Materials). A 0.5 mm layer of the same epoxy was used to mask some of the sensors (see SI). The masked sensors, no longer able to detect nanotag binding, would serve as electrical signal references (see Methods -Electronics). Surface Preparation. The assembled chips were thoroughly washed with acetone, methanol, isopropanol, and de-ionized water. A 10-min UV ozone treatment (UVO Cleaner Model 42, Jelight) was used to remove organic residues. To form the base layer of the biofunctionalization, a 2% solution of polyethyleneimine (PEI, CAS 9002-98-6, Sigma-Aldrich) in deionized water was applied to the chip surface for 2 min. The chips were then rinsed with deionized water and then baked at 150°C for 5 min to solidify the adsorbed PEI.
Multiplex Protein Assay in PBS with Nanotag Amplification

Multiplex Protein Assays.
For multiplex experiments with three distinct probes, the probes (anti-IL-1␣ and anti-TNF-␣ at 500 g/ml, and BSA at 1%, i.e., 10 mg/ml) were manually deposited with a pipette in the form of 0.2-l droplets onto selected sites, each covering several sensors, of a single chip. For multiplex experiments with eight distinct capture probes, the probes (anti-IL-1␣, anti-TNF-␣, anti-CEA, anti-G-CSF, anti-IFN-␥, anti-lactoferrin, anti-eotaxin, at 1%) were robotically spotted in the form of 2-nL droplets onto individual sensors. Additional control sensors were functionalized with epoxy resin. The spotted chips were incubated overnight at 4°C in a humidifier. The chips were then rinsed twice with blocking buffer (1% BSA and 0.2% Tween 20 in PBS), and further blocked with the same buffer for 60 min at room temperature to reduce nonspecific surface binding sites. Samples consisting of multiple proteins in the same solution were then prepared by mixing several analytes (TNF-␣; IL-10; IL-1␣; G-CSF; lactoferrin; CEA; eotaxin; and IFN-␥) to the desired concentrations in either PBS buffer or in 50% human serum (balance PBS). Twenty microliters of this sample solution were pipetted into the reagent well of a chip and incubated for 1 h at room temperature, so that all of the sensors on the chip were exposed to the same multiprotein sample solution. Subsequently, the chip was rinsed twice with rinsing buffer (0.1% BSA and 0.2% Tween 20 in PBS). A multiplex linker antibody solution was prepared consisting of multiple biotinylated antibodies, one type for each potential analyte, at a concentration of 2 g/ml in PBS. Twenty microliters of this linker antibody solution were incubated in the reagent well of the chip for 1 h at room temperature. With the linker solution still in place, the chips were then transferred over to the measuring station for MNT-based analyte quantification.
hCG Assays. All chips were uniformly functionalized with a single capture probe, anti-hCG at 1 mg/ml, incubated overnight at 4°C, then rinsed twice with blocking buffer. Pure serum samples spiked with hCG to 2.5, 25, 250, and 2,500 IU/L were supplied by the US National Cancer Institute and diluted 1:1 with PBS buffer. Analyte incubation was 1 h, and linker antibody at 5 g/ml in PBS, was incubated for 90 min. With the linker solution still in place, the chips were then transferred over to the measuring station for MNT-based analyte quantification. The concentrations of hCG after dilution with PBS have been converted by using 1 IU/L ϭ 1.9 pM (25, 26).
MNT-Based Analyte Quantification. To remove the linker antibody solution and to confirm signal baseline stability, the chips were rinsed with MNT-free PBS buffer several times. Although the associated wet/dry transitions did occasionally shift the baseline slightly, these shifts were reversible and usually negligible compared with the signals of interest. The absolute signal level on contact with MNT-free buffer was taken to be zero. The MNT-free buffer solution was then aspirated from the well and replaced with 50 l of streptavidin-coated MNT stock solution (MACS 130 -048-102, Miltenyi Biotec; for additional details, see SI). The nanotag solution was incubated without stirring for the next 20 min at room temperature. The signal levels at the end of this 20-min nanotag incubation time were taken as the final result of the assay.
Optional Nanotag Amplification. At the end of the initial 20-min MNT incubation period, the well was rinsed five times with PBS, and then refilled with 50 l of the biotinylated linker antibody solution. This solution was incubated for five minutes, attaching biotinylated antibodies to the already adsorbed MNTs. Because these linker antibodies can have multiple biotin sites, binding sites for additional MNTs were created this way on the existing MNTs. After five minutes, the solution was aspirated, the well rinsed five times with PBS, and 50 l of MNT stock solution were added, resulting in the generation of an additional MNT binding signal. This amplified the signal levels by a factor of approximately 2ϫ with each iteration (see SI for additional data).
Electronics. An alternating current of 7 Arms at 500 Hz was applied to each sensor. An alternating in-plane tickling field of 80 Oerms at 208 Hz was applied perpendicular to the sensor segments to establish a magnetic signal baseline, which is minimally perturbed in the vicinity of any nanotags. This perturbation of baseline signal is our net signal. A steady bias field of 50 Oe was also applied along the longitudinal direction of the sensor segments to facilitate a coherent (low noise) rotation of the magnetic domains of the sensor in response to the 208-Hz tickling field. The signal level was measured by performing a fast Fourier transform of the voltage across each sensor once per second and recording the magnitude of the (amplitude modulation generated) 708-Hz spectral component, which in this setup is primarily a measure of the tickling field strength in the immediate vicinity of the sensor. To reduce the common mode and sensor drift, every functionalized sensor was measured differentially against a reference sensor, that is, against a sensor that was covered with a layer of epoxy thick enough to positively prevent any MNT detection. Additional details of this measurement setup are described elsewhere (27) . S2 . Magnetic nanotags. After the MNT-based analyte quantification, the MNT solution was aspirated and the chips were rinsed twice with de-ionized water to remove salt residues that otherwise would obscure bound MNTs. Chips were then metallized with 1 nm AuPd by DC sputtering (Hummer V) to enhance image contrast. Images were obtained with an FEI Sirion XL30 scanning electron microscope. The diameter of the magnetic nanotags, commercially available Miltenyi MACS 130 -048-102, is stated by Miltenyi to be 50 nm (no size distribution is given). Upon metallization and inspection in the SEM, these particles appear as roughly 35-nm irregular spheres as shown above, with frequent multiparticle clusters. Neither the stock concentration nor the structure of these particles is disclosed by the manufacturer. However, MACS nanotags appear to contain only a small fraction of magnetic material dispersed throughout a non-magnetic organic matrix to which the functionalization (streptavidin) is bound. This particularly high coverage density was achieved by applying MACS stock solution to a test chip that had been functionalized with biotinylated BSA. As a precursor to the sandwich immunoassays described in the main section of the paper, we performed a non-sandwich assay as illustrated above on an earlier generation of chips. (These earlier chips exhibited a reversible signal baseline shift during wet-dry transitions, as can be seen in Figure 3D from time Ϫ2 Ͻ t Ͻ 0 minutes.) This behavior has been nearly eliminated on recent chips through better passivation. In this assay, the analyte is biotinylated anti-IFN-␥, which is captured by IFN-␥ functionalized sensors and quantified with streptavidin-coated magnetic nanotags. In step (A), probe sensors are functionalized with a 1 l droplet of IFN-␥, 100 g/ml in PBS buffer, for 30 min at 4°C. Control sensors are functionalized with a 1 l droplet of IL6-sR, 100 g/ml in PBS buffer. The functionalized chip is then rinsed with a 1% BSA in 1x PBS buffer solution to block non-specific adsorption sites. In step (B), the chip well is filled with 100 l of analyte, for example, biotinylated anti-IFN-␥ 670 pM (100 ng/ml) in PBS buffer. The analyte is incubated in the entire well of the chips for 1. S4 . Test of sensor geometry and its effect on sensitivity. This figure illustrates how we evaluated the effect of sensor segment width while keeping most other parameters of the sensors equal. For illustrative purposes, a simplified sensor is shown (A). The simplified sensor on the left has three segments, each 3-m wide. The simplified sensor on the right has six segments, each 1.5-m wide. Thus, the total sense current i, the resistance, the sensing area, and the sense current density of these two sensors can all be identical. To ensure identical experimental conditions for both sensor types, custom chips were fabricated that carried both sensors variants inside the same reaction well. The entire reaction well was uniformly functionalized with 100 l biotinylated BSA (stock of 200 g/ml), and incubated for 30 min at room temperature. No analyte was necessary, since the MNTs can bind directly to the biotinylated BSA. The chips were rinsed twice with PBS and transferred over to the measuring station for MNT quantification. Our data indicates that patterning sensors more finely, as shown on the right, results in better sensitivity. The median curve for each type of sensor is shown (n ϭ 4 curves for each sensor type), with the error bars indicating Ϯ 1 S.D. The signal from the 1.5 m sensors was consistently stronger than that from the 3.0 m sensors (B). This result proves that sensitivity gains can be realized by using more finely patterned sensors with submicron line widths (6) . The main reason for the sensitivity gain is that, as we scale down the segment width while keeping the overall sensor area constant, the signal per magnetic nanotag increases faster than the inverse of the segment width. Consequently, even if the same number of magnetic nanotags is captured by the 3.0-m sensor and the 1.5-m sensor, the latter generates a larger signal. Such scaling relations appear to be common among biosensors and argue favorably for adopting submicron-and even nanoscale sensors (7). , and the applied sample contained 5.7 pM TNF-␣ in PBS. The initial MNT-based analyte quantification was performed from 0 Ͻ t Ͻ4.5 min. From 4.5 Ͻ to Ͻ6.5 min, the chip was first washed, then briefly incubated with biotinylated linker molecules, which attach to the already adsorbed streptavidin-coated MNTs. The already adsorbed MNTs are thus able to capture additional MNTs. A second charge of MNTs is then incubated from t Ͼ6.5 min. As can be seen from the TNF-␣ sensors, additional MNTs are captured and a second binding curve is observed, which levels off at almost twice the signal level of the original MNT binding curve. . Quadplex protein assay with 50% zero-analyte controls. A zero-analyte control is the signal obtained from a realistic assay where the analyte in question is entirely absent from the sample. The ideal signal in this case should be zero, but especially in multiplex assays the actual signal is often higher due to cross-reactivity with non-matching but highly available antigens. Four regions of the chip were functionalized as indicated, each with one of the four capture antibodies (anti-TNF-␣, anti-IL-10, anti-VEGF, and anti-IL-1␣). The chip was then exposed to a subset of the four potentially recognized analytes, namely TNF-␣ at 58 pM and IL-10 at 54 pM in PBS, which left VEGF sensors and IL-1␣ sensors to serve as zero-analyte negative controls. Fourteen sensors were subsequently chosen from the sensor array to measure the signals from each of the four regions with a certain redundancy (ranging from replicate to quadruple). The initial MNT quantification was enhanced with one round of nanotag amplification. As shown above, only the sensors with matching analytes (TNF-␣ and IL-10 in this case) gave large signals as expected. The numbers above the bars indicate the actual analyte concentrations present, and the median signals reported, for each analyte. Signal variation among sensors with identical functionalization is quite small in most cases, but the chip's sensitivity appears to vary with the type of functionalization, since IL-10 gives a much larger signal than TNF-␣ at similar concentrations. This is reasonable considering that the analyte affinity of each functionalization can be different. The small but non-zero signals on the VEGF and IL-1␣ sensors could be due to a small amount of cross-reactivity, which is common in multiplex protein assays and which also depends on the matching and quality of the assay antibodies. At this level, the signal is no longer dependent on the analyte concentration, presumably because it is being dominated by non-specific binding that happens to occur on this particular set of probes. This limited the initial assay sensitivity to VEGF concentrations of 20 pM at best. A possible source of non-specific binding is the cross reactivity of VEGF capture probes with biotinylated impurity antibodies in the buffer solution. To optimize the assay, additional anti-VEGF antibodies from various vendors were evaluated until a better performing set was found by trial and error. The new capture probes had less non-specific binding, but similar specific analyte affinity. As a result, the signal floor was lowered to approximately 2.5 V, which allowed the signal vs. concentration curve to extend down to approximately 2 pM. S1 , sits in a socket at the center of a Helmholtz coil, which is powered by a small consumer audio amplifier. The signals from the chip are amplified by a multichannel, low noise, custom built preamplifier. The preamplifier is connected to an 18-bit multichannel data acquisition card inside a small desktop PC. The monitor on the far right is displaying signal vs. time curves from real-time nanotag binding.
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